Refer to approved product information for complete indication.
Aranesp® (darbepoetin alfa)
Aranesp® is used for the treatment of anaemia associated with chronic renal failure, or resulting from concomitantly administered chemotherapy when treating a non-myeloid malignancy.
Aranesp® Product Information
BLINCYTO® is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). BLINCYTO® is indicated for the treatment of minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL) in patients in complete haematological remission.
Note to indication: the indications in Philadelphia positive, MRD positive and paediatric patients were approved based on phase II, non-randomised evidence. An improvement in clinical outcomes by direct prospective comparison in a randomised setting relative to other standard-of-care salvage therapies has not been established.
BLINCYTO® Product Information
IMLYGIC™ (talimogene laherparepvec)
IMLYGIC™ is an oncolytic immunotherapy derived from recombinantly engineered herpes simplex virus type-1 and is indicated as a monotherapy for the treatment of melanoma in patients with unresectable cutaneous, subcutaneous or nodal lesions after initial surgery.
IMLYGIC™ Product Information
KYPROLIS®, as part of combination therapy with dexamethasone or lenalidomide and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
KYPROLIS® Product Information
A long acting leukocyte growth factor used to decrease the duration of severe neutropenia and so reduce the incidence of infection in patients with cancer.
Neulasta® Product Information
A leukocyte growth factor used to decrease the duration of neutropenia and incidence of infection in patients with cancer, and for use in patients with severe chronic neutropenia and HIV patients with neutropenia. It is also used in mobilisation of peripheral blood progenitor cells.
NEUPOGEN® Product Information
A thrombopoietin mimetic used to treat low blood platelet counts in adults with chronic immune thrombocytopenic purpura (ITP).
Nplate® Product Information
- For the treatment of osteoporosis in postmenopausal women. Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures.
- As treatment to increase bone mass in men with osteoporosis at increased risk of fracture.
- As treatment to increase bone mass in men with osteopaenia receiving androgen deprivation therapy for non-metastatic prostate cancer.
Prolia® Product Information
Repatha™ is indicated in adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease (DVC) in combination with a statin or statin with other lipid lowering therapies, or in combination with other lipid lowering therapies in patients who are statin-intolerant. Repatha™ is also indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.
Repatha™ Product Information
Sensipar® (cinacalcet HCl)
Sensipar® is used for the treatment of secondary hyperparathyroidism in dialysis patients with end stage renal disease, hypercalcaemia in patients with parathyroid carcinoma and primary hyperparathyroidism in patients for whom parathyroidectomy is not an option.
Sensipar® Product Information
An EGFR inhibitor used to treat patients with wild-type RAS colorectal cancer that has spread to other parts of the body in combination with chemotherapy or after failure of chemotherapy.
Vectibix® Product Information
XGEVA® is indicated for the prevention of skeletal related events in patients with bone metastases from solid tumours.
XGEVA® Product Information